申请人:Jiangsu Nhwaluokang Pharmaceutical
Research and Development Co., Ltd.
公开号:EP3549945A1
公开(公告)日:2019-10-09
The present invention relates to the field of medicine, and particularly relates to a water-soluble allopregnenolone (3β,5α-tetrahydroprogesterone) derivative, a pharmaceutical composition comprising the same, and use thereof in prevention or treatment of central nervous system diseases, in sedation and hypnosis, in treatment of Alzheimer's disease, in treatment of epilepsy or in treatment of depression, especially postpartum depression.
本发明涉及医药领域,尤其涉及一种水溶性异孕烯雌酮(3β,5α-四氢黄体酮)衍生物,一种包含该衍生物的药物组合物,以及其在预防或治疗中枢神经系统疾病、镇静和催眠、治疗阿尔茨海默病、治疗癫痫或治疗抑郁症(尤其是产后抑郁症)中的用途。